CRISP风险评估与决策支持工具在基层医疗中提高结直肠癌风险分层筛查:随机对照试验研究方案
本研究为II期多中心个体随机对照试验方案,在基层医疗中比较使用CRISP工具进行标准化咨询与常规 care 对结直肠癌风险适宜筛查的影响。计划纳入732名50-74岁就诊患者,按诊所分层随机分组,主要结局为12个月时风险适宜筛查。
要点
- CRISP工具旨在实现基于绝对风险的精准筛查。
- 主要结局为12个月时风险适宜筛查,用基线和客观健康服务数据测量。
- 次要结局包括癌症风险感知、焦虑、癌症担忧、筛查意向和健康服务利用。
核心结论
- 该试验旨在检验CRISP工具在基层医疗中能否增加风险适宜的结直肠癌筛查。
研究设计与样本
- II期多中心个体随机对照试验,计划纳入732名50-74岁全科就诊患者,按诊所分层随机分组。
- 干预组接受使用CRISP工具的标准化咨询,对照组接受标准化癌症预防信息。
关键数值与推荐
- 主要结局为12个月时风险适宜筛查,使用结直肠癌风险基线和客观健康服务数据测量。
- 次要结局包括1、6、12个月时的癌症风险感知、焦虑、癌症担忧、筛查意向和健康服务利用。
临床怎么用
- 若有效,该工具可在基层医疗中基于个体绝对风险实施风险分层筛查。
局限性
- 本文为研究方案,尚未报告试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia and New Zealand have the highest incidence rates of colorectal cancer worldwide. In Australia there is significant unwarranted variation in colorectal cancer screening due to low uptake of the immunochemical faecal occult blood test, poor identification of individuals at increased risk of colorectal cancer, and over-referral of individuals at average risk for colonoscopy. Our pre-trial research has developed a novel Colorectal cancer RISk Prediction (CRISP) tool, which could be used to implement precision screening in primary care. This paper describes the protocol for a phase II multi-site individually randomised controlled trial of the CRISP tool in primary care. METHODS: This trial aims to test whether a standardised consultation using the CRISP tool in general practice (the CRISP intervention) increases risk-appropriate colorectal cancer screening compared to control participants who receive standardised information on cancer prevention. Patients between 50 and 74 years old, attending an appointment with their general practitioner for any reason, will be invited into the trial. A total of 732 participants will be randomised to intervention or control arms using a computer-generated allocation sequence stratified by general practice. The primary outcome (risk-appropriate screening at 12 months) will be measured using baseline data for colorectal cancer risk and objective health service data to measure screening behaviour. Secondary outcomes will include participant cancer risk perception, anxiety, cancer worry, screening intentions and health service utilisation measured at 1, 6 and 12 months post randomisation. DISCUSSION: This trial tests a systematic approach to implementing risk-stratified colorectal cancer screening in primary care, based on an individual's absolute risk, using a state-of-the-art risk assessment tool. Trial results will be reported in 2020. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry, ACTRN12616001573448p . Registered on 14 November 2016.
引用
- Walker JG, Macrae F, Winship I, et al. The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial. Trials. 2018. PMID: 30045764. doi:10.1186/s13063-018-2764-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。